WuXi Biologics (Cayman) Inc. (2269.HK)
| Previous Close | 11.300 |
| Open | 11.300 |
| Bid | 11.680 x 0 |
| Ask | 11.700 x 0 |
| Day's Range | 11.280 - 11.960 |
| 52 Week Range | 10.140 - 52.450 |
| Volume | |
| Avg. Volume | 44,113,661 |
| Market Cap | 48.173B |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | 17.70 |
| EPS (TTM) | 0.660 |
| Earnings Date | Aug 21, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.99 |
PR NewswireWuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI™ in 2,000L GMP Manufacturing
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has successfully accomplished 2,000L drug substance (DS) GMP manufacturing by utilizing its proprietary ultra-intensified fed-batch bioprocessing platform WuXiUI™. The platform achieved a titer of 18 g/L, a 4-fold increase compared to conventional fed-batch process, demonstrating the high efficiency of WuXiUI™ in improving productivity.
PR NewswireWuXi Biologics Reports Solid 2024 Interim Results
WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2024 ("Reporting Period").
PR NewswireWuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Medigene AG (Medigene, FSE: MDG1, Prime Standard) today announced that they have entered into a three-year, multi-target strategic partnership to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors. The collaboration combines the respective expertise of each company with Medigene's 3S (sensitiv
